OR WAIT null SECS
The HCPLive venous thromboembolism page is a resource for medical news and expert insights on VTE. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for thrombotic disease, and more.
January 31, 2024
Article
A recent analysis found risk factors linked to an embolism after VTE included Black race, interstitial fibrosis, advanced-stage disease, and increased operative duration.
December 12, 2023
Presented at ASH 2023, findings of a new study showed patients with sickle cell disease and venous thromboembolism have longitudinal worsening of left ventricular diastolic and right-sided cardiac function.
September 18, 2023
Anthos Therapeutics halts their phase 2 AZALEA-TIMI 71 trial due to significant reduction in bleeding events with abelacimab, making it a potential breakthrough in anticoagulation therapy for atrial fibrillation.
January 18, 2023
Results of the PREVENT CLOT study indicate use of aspirin was as effective as low-molecular-weight heparin for reducing incidence of mortality in patients hospitalized with a traumatic fracture.
September 20, 2022
A reduction in aspirin use was associated with significantly less bleeding and health care use, without an increase in thrombotic outcomes.
August 24, 2022
A recent study indicated no evident VTE risk in patients with eczema, despite FDA black box warnings for the drug class.
July 06, 2022
New findings suggest low-dose rivaroxaban plus aspirin was associated with lower VTE risk compared with aspirin alone.
June 17, 2022
The prevalence rate of VTE was 2% among a large population of SCD patients in Nigeria.
May 24, 2022
Data show the presence of five and six risk factors increased the risk of VTE exponentially to 10.9% and 25%, respectively
March 29, 2022
In a population aged 70 years and older, a remote history of VT was associated with an increased risk of VT independent of other factors.